News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–54
Matches
54
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

54 matching headlines

Ticker or company: BNTXMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Biontech SE (BNTX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Biontech SE (BNTX)'s financial health, indicating a robust financial status but average operating efficiency. The company's financial score is 7.39, ranking it 125 out of 385 in the Biotechnology & Medical Research industry. Recent quarterly results show a …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

2 Major Reasons to Buy Moderna Stock Before July 31

Quick Read Moderna heads into Q2 earnings on a five-quarter beat streak, with traders pricing an 84% chance of another beat and a 0.12 put/call ratio. BNTX shares Moderna's ~$23B market cap but posted a 35% YoY revenue decline in Q1 while Moderna compounded …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Earnings Main company 🇺🇸 United States

Biontech Se Sponsored Adr (BNTXN) Q4 2022 Earnings Report - Results, Call & Slides

This article provides an in-depth report on BioNTech SE's (BNTXN) Q4 2022 earnings, highlighting that the company beat both EPS and revenue expectations. It details the actual EPS of $183.86 against a consensus of $154.43 and actual revenue of $76.15B versus expected revenue of …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BX:22UA

This article provides a financial report indicating the enterprise value to revenue forward for BioNTech SE Sponsored ADR (BX:22UA). The report, presented by TradingView and utilizing data from ICE Data Services and FactSet, specifies a period, value, and change for this financial metric, noting …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

(BNTX) Price Dynamics and Execution-Aware Positioning

The article provides an AI-generated analysis of Biontech Se (NASDAQ: BNTX) stock, indicating weak sentiment across all time horizons and supporting a short bias. It highlights a significant 35.4:1 risk-reward short setup targeting a 10.4% downside. The analysis presents institutional trading strategies, including long, …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Biontech SE (BNTX) Cash Flow

This article provides a detailed cash flow statement for Biontech SE (BNTX), covering both annual and quarterly data across operating, investing, and financing activities. It presents key financial metrics such as operating cash flow, capital expenditures, and free cash flow, along with year-over-year percentage …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Analyst action Main company 🇺🇸 United States

BNTX|Biontech SE|Price:89.330|Chg%:-2.730

This article provides a detailed financial overview and analyst ratings for BioNTech SE (BNTX). It highlights the company's healthy fundamentals, significant growth potential, and "Fairly Valued" status, despite a recent stock price dip and expectations for a short-term downward trend. Analysts currently rate BNTX …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Biontech SE (BNTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Biontech SE (BNTX), listing its major shareholders and institutional holdings as of recent reporting periods. It provides a breakdown of shareholder types and highlights significant changes in shareholdings by various entities. The article also includes related ETF …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

BioNTech SE Revenue Breakdown – NASDAQ:BNTX

BioNTech SE (NASDAQ: BNTX) reported a total revenue of $3.37 billion USD last year. The majority of this revenue, $3.24 billion USD, came from its Immunotherapy Technologies segment, an increase from $2.98 billion USD in the previous year. The United States was the largest …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Earnings Main company 🇺🇸 United States

BioNTech SE (0A3M) Q3 2024 Earnings Report - Results, Call & Slides

This article provides a detailed report on BioNTech SE's (0A3M) Q3 2024 earnings, highlighting a significant beat on both EPS and revenue expectations. The company reported actual EPS of $0.92 against a consensus of -$1.78, and revenue of $1.37 billion compared to an expected …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Earnings Main company 🇺🇸 United States

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring

BioNTech is shifting its focus from COVID-19 vaccines to the oncology market, which is projected to reach $516.2 billion by 2035. The company has over 25 ongoing oncology clinical trials, with promising candidates like pumitamig, a bispecific antibody developed with Bristol Myers Squibb, which …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

The BioNTech Omicron BA.4/ BA.5 Booster - BioNTech SE bets on updated protection

BioNTech's Omicron BA.4/BA.5-adapted COVID-19 booster, developed with Pfizer, targets newer Omicron subvariants with an updated mRNA formulation. This booster has received regulatory clearances in various regions, including the EU and US, showing improved immune responses compared to the original vaccine. The product is a …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

BioNTech sets Aug. 4 webcast for second-quarter update

BioNTech SE (Nasdaq: BNTX) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. On the same day, the company will host a conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss the results and provide …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Kalkine Media Earnings Main company 🇺🇸 United States

BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4

BioNTech SE (Nasdaq: BNTX, 0A3M), a biopharmaceutical company, announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026. Concurrently, the company will host a live conference call and webcast at 8:00 a.m. ET (2:00 p.m. CET) to discuss its quarterly …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Earnings Main company 🇺🇸 United States

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech SE is scheduled to announce its second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. ET to discuss the results and provide a corporate update. Investors …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
globenewswire.com Earnings Main company 🇺🇸 United States

BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt

MAINZ, Deutschland, 21. Juli 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Dienstag, den 4. August 2026, die Ergebnisse für das zweite Quartal 2026 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 14:00 Uhr MEZ (8:00 …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
ad-hoc-news.de Earnings Main company 🇺🇸 United States

The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges including cold chain requirements, and its safety profile based …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Balance sheet Main company 🇺🇸 United States

(BNTX) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of BioNTech SE (NASDAQ: BNTX), highlighting a near-term weak sentiment that may lead to a resumption of long-term weakness. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The …

BNTX main company
Sharemaestro market context Price below Trend Line 52 weeks -16.0% BNTX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context